Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood

Anesthesia and Analgesia

Volumn 114, Issue 6, 2012, Pages 1182-1188

  Dirkmann, Daniel ^a   Görlinger, Klaus ^a   Gisbertz, Caroline ^a   Dusse, Fabian ^a   Peters, Jürgen ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CYTOCHALASIN D; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; SODIUM CHLORIDE; THROMBIN; TRANEXAMIC ACID;

ARTICLE; BLOOD CLOT; BLOOD CLOTTING DISORDER; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CLOT LYSIS INDEX; FIBRINOLYSIS; HUMAN; HYPERFIBRINOLYSIS; MEASUREMENT; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ADULT; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CYTOCHALASIN D; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FACTOR VIIA; FACTOR XIII; FEMALE; FIBRINOLYSIS; HUMANS; MALE; PLATELET ACTIVATION; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; YOUNG ADULT;

EID: 84861509156     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31823b6683     Document Type: Article

References (58)

1. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003;16:17-20
2. Robbie LA, Bennett B, Croll AM, Brown PA, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996;75:127-33
3. Gorlinger K. Coagulation management during liver transplantation [in German]. Hamostaseologie 2006;26:64-76
4. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008;64:1211-7
5. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, Katabami K. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res 2009;124:608-13
6. Schochl H. Coagulation management in major trauma [in German]. Hamostaseologie 2006;26:52-5
7. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009;67:125-31
8. Palmer JD, Francis DA, Roath OS, Francis JL, Iannotti F. Hyperfibrinolysis during intracranial surgery: effect of high dose aprotinin. J Neurol Neurosurg Psychiatry 1995;58:104-6
9. Goh KY, Tsoi WC, Feng CS, Wickham N, Poon WS. Haemostatic changes during surgery for primary brain tumours. J Neurol Neurosurg Psychiatry 1997;63:334-8
10. Pfanner G, Kilgert K. Haemorrhagic complications in obstetrics [in German]. Hamostaseologie 2006;26:56-63
11. Hofer S, Schreckenberger R, Heindl B, Gorlinger K, Lier H, Maul H, Martin E, Weigand MA. Hemorrhaging during pregnancy [in German]. Anaesthesist 2007;56:1075-89
12. Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992;68:250-2
13. Adrie C, Monchi M, Laurent I, Um S, Yan SB, Thuong M, Cariou A, Charpentier J, Dhainaut JF. Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest: implication of the protein C anticoagulant pathway. J Am Coll Cardiol 2005;46:21-8
14. Skagius E, Siegbahn A, Bergqvist D, Henriksson AE. Fibrinolysis in patients with an abdominal aortic aneurysm with special emphasis on rupture and shock. J Thromb Haemost 2008;6:147-50
15. Görlinger K, Jambor C, Hanke AA, Dirkmann D, Adamzik M, Hartmann M, Rahe-Meyer N. Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis. Transfus Med Hemother 2007;34:396-411
16. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008;100:792-7
17. Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006;4:411-6
18. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006;17:75-81
19. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombinactivatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006;25:1247-52
20. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, de Groot PG. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002;99:175-9
21. Antovic JP, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost 2003;90:620-7
22. Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis 2008;19:106-8
23. Hartert H. Thrombelastography, a method for physical analysis of blood coagulation [in German]. Z Gesamte Exp Med 1951;117:189-203
24. Dirkmann D, Hanke AA, Gorlinger K, Peters J. Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects. Acta Anaesthesiol Scand 2007;51:640-3
25. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a metaanalysis of randomized control trials. Ann Surg 2008;248:61-8
26. Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA. Thrombin generation and fibrinolysis in antifactor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010;16:510-7
27. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Innerhofer P. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo. Br J Anaesth 2008;100:307-14
28. Haas T, Fries D, Velik-Salchner C, Reif C, Klingler A, Innerhofer P. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008;106:1360-5
29. Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII supplementation increases clot firmness in rotation thromboelastometry (ROTEM). Thromb Haemost 2010;104:1-7
30. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994;83:1006-16
31. Devine DV, Bishop PD. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization. Semin Thromb Hemost 1996;22:409-13
32. Katori N, Tanaka KA, Szlam F, Levy JH. The effects of platelet count on clot retraction and tissue plasminogen activatorinduced fibrinolysis on thrombelastography. Anesth Analg 2005;100:1781-5
33. Nagy B Jr, Simon Z, Bagoly Z, Muszbek L, Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost 2009;102:83-9
34. Lang T, Toller W, Gutl M, Mahla E, Metzler H, Rehak P, Marz W, Halwachs-Baumann G. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004;2:147-53
35. Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol 2000;54:260-4
36. Shainoff JR, Estafanous FG, Yared JP, DiBello PM, Kottke- Marchant K, Loop FD. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;108:437-45
37. Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006;54:26-33
38. Tacke F, Fiedler K, von Depka M, Luedde T, Hecker H, Manns MP, Ganser A, Trautwein C. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int 2006;26:173-81
39. Korte WC, Szadkowski C, Gahler A, Gabi K, Kownacki E, Eder M, Degiacomi P, Zoller N, Devay J, Lange J, Schnider T. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009;110:239-45
40. Bereczky Z, Katona E, Muszbek L. Fibrin stabilization (factor XIII), fibrin structure and thrombosis. Pathophysiol Haemost Thromb 2003;33:430-7
41. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999;99:299-304
42. Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990;75:1455-9
43. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008;6:190-205
44. Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac and vascular diseases. Front Biosci 2007;12:2530-45
45. Undas A, Brzezinska-Kolarz B, Brummel-Ziedins K, Musial J, Szczeklik A, Mann KG. Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects. J Thromb Haemost 2005;3:2015-21
46. Sorensen B, Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation: haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006;96:446-53
47. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008;122:117-23
48. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004;103:2157-61
49. Broze GJ Jr. Thrombin-dependent inhibition of fibrinolysis. Curr Opin Hematol 1996;3:390-4
50. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997;99:2323-7
51. Mosnier LO. Platelet factor 4 inhibits thrombomodulindependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J Biol Chem 2011;286:502-10
52. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, Leebeek FW, Van der Meer J, Van Marwijk Kooij GM, Van der Linden PW. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002;8:649-56
53. Lewis NR, Brunker P, Lemire SJ, Kaufman RM. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 2009;49:689-95
54. Conen A, Weisser M, Tsakiris DA, Siegemund M. Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding. BMC Infect Dis 2007;7:34
55. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000;20: 2511-8
56. Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998;79:371-7
57. Vigue B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage-from theory to practice. Crit Care 2009;13:209-18
58. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995;82:283-92